Hubei Biocause Pharmaceutical Co., Ltd. (SHE:000627)

SHE:000627 Revenue

Hubei Biocause Pharmaceutical had revenue of 4.54B CNY in the quarter ending September 30, 2024, a decrease of -41.47%. This brings the company's revenue in the last twelve months to 40.70B, down -22.90% year-over-year. In the year 2023, Hubei Biocause Pharmaceutical had annual revenue of 48.28B, down -2.10%.

• Revenue (ttm): 40.70B
• Revenue Growth: -22.90%
• P/S Ratio: 0.19
• Revenue / Employee: 23.06M
• Employees: 1,765
• Market Cap: 7.75B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	48.28B	-1.03B	-2.10%
Jan 1, 2023	49.31B	614.72M	1.26%
Jan 1, 2022	48.70B	7.57B	18.40%
Dec 31, 2020	41.13B	-8.54B	-17.20%
Dec 31, 2019	49.67B	19.79B	66.25%